EMA Medicine safety communications
Adakveo: lack of effect;referral - article 20 procedure
Published by European Medicines Agency: · Ref. EMEA/H/A-20/1525/C/4874/0013
Summary
Lack of effect;Referral - Article 20 procedure
Medicine
Adakveo
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): Crizanlizumab
- Therapeutic area: Anemia, Sickle Cell
- ATC code: B06AX01
Measures and alternatives
- Regulatory outcome: Revocation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗